The role of metabolic syndrome in the course and outcome of NSAID-gastropathy

Metabolic syndrome is a significant global problem. Many of these patients have to take NSAIDs for a long time as a baseline treatment for associated diseases, the side effects of which on the gastric mucosa known to many specialists. The purpose of the study was to determine the role of metabolic syndrome in the course and outcome of NSAID-gastropathy. Selected 84 patients from 44 to 69 years, divided into 3 groups: 1 group - 31 people with NSAID-gastropathy and MS, 2 group - 24 people with NSAID-gastropathy and without MS, 3 group - 33 patients with MS, taking NSAIDs without NSAID gastropathy. Clinical and anamnestic data were determined, anthropometric parameters were assessed, the biochemical blood test was performed to determine the lipid spectrum, fasting capillary blood glucose level and esophagogastroduodenoscopy (EGDS) – before and 4 weeks after therapy with proton pump inhibitors (PPI) for all subjects. Data processing performed using the software package Excel, Annova and Statistica 10. The process of GM erosions healing in subjects with MS and NSAID-gastropathy takes a longer period. The dominant factors in the development of erosive lesions are the levels of HDL cholesterol, degree of hypertension and H. pylori infection. Duration of treatment is mainly influenced by LDL cholesterol levels, TG and TH levels, and the degree of AH. Conclusions. MS makes a negative contribution during NSAID gastropathy.